NCT02653118
Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 18 versions: 7 with changes below, 11 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 2 words
- Trial sites expanded: 0 → 13 locations
- Publications: details revised at 2 of 2 entries
- Notable Eligibility criteria shortened, about 12 words
- Publications: details revised at 1 of 2 entries
- Notable Primary and study completion dates: Jan 1, 2024 to Jan 1, 2040
- Primary endpoint revised
- Minor Publications: 1 to 2v13
- Minor Primary and study completion dates: Jan 2024 to Jan 1, 2024
- Start date: Jan 2016 to Jan 22, 2016
- Minor Trial status: Not Yet Recruiting to Active, Not Recruitingv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Participants received the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543). No study vaccination will be administered in study V503-021.
Participants received GARDASIL (0.5 mL in a 3-dose regimen) from a Denmark, Norway, or Sweden site in the base study (V503-001, NCT00543543) and were offered the selected dose formulation of V503 (0.5 mL in a 3-dose regimen) at the conclusion of the base study. V503 vaccination was voluntary and not a condition for inclusion in Cohort 2. No study vaccination will be administered in study V503-021.
Biologicals: V503, GARDASIL
Sites
13 sites in 3 countries
Norway 6, Denmark 5, Sweden 2